Pasithea Therapeutics Corp. (KTTA)
| Market Cap | 19.83M +326.3% |
| Revenue (ttm) | n/a |
| Net Income | -20.43M |
| EPS | -2.91 |
| Shares Out | 24.94M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 187,717 |
| Open | 0.8332 |
| Previous Close | 0.8400 |
| Day's Range | 0.7928 - 0.8399 |
| 52-Week Range | 0.2810 - 2.0600 |
| Beta | 0.22 |
| Analysts | Strong Buy |
| Price Target | 3.00 (+277.22%) |
| Earnings Date | May 22, 2026 |
About KTTA
Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary scle... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for KTTA stock is "Strong Buy" and the 12-month stock price target is $3.0.
News
Pasithea Therapeutics appoints Kartik Krishnan as chief medical officer
Pasithea Therapeutics (KTTA) announced the appointment of Kartik Krishnan as chief medical officer of the company, effective May 1. Krishnan will oversee all clinical development and medical strategy ...
Pasithea Therapeutics Announces Appointment of Kartik Krishnan, M.D., Ph.D. as Chief Medical Officer
MIAMI, May 04, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocycl...
Pasithea Therapeutics announces U.S. FDA granted RPDD to PAS-004
Pasithea Therapeutics (KTTA) announced that the U.S. Food and Drug Administration, FDA, has granted Rare Pediatric Disease Designation, RPDD, to PAS-004 for treatment of Neurofibromatosis type-1. The ...
Pasithea Therapeutics Announces Grant of Fast Track Designation by FDA to PAS-004 for Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) Causing Significant Morbidity
MIAMI, April 01, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocy...
Pasithea Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Pasithea Therapeutics (Nasdaq: KTTA) will present to Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 25, 2026, 4:00 PM ET
Pasithea Therapeutics provides updated timeline on PAS-004 programs
Pasithea Therapeutics (KTTA) provided updated timelines on its ongoing clinical trials in advanced cancer and adult NF1-PN patients. Ongoing Phase 1/1b clinical trial in adult patients with NF1-PN: Pa...
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
MIAMI, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation oral mac...
Pasithea Therapeutics initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Sara Nik initiated coverage of Pasithea Therapeutics (KTTA) with a Buy rating and $3 price target The firm says the company has a next-generation MEK inhibitor “set
3 Penny Stocks to Watch Now, 12/2/25
Pasithea Therapeutics ($KTTA), Aditxt ($ADTX), and HeartBeam ($BEAT) are the 3 Penny Stocks to watch on December 2, 2025, based on TipRanks’ Penny Stock Screener tool. Penny stocks are shares usually ...
Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
MIAMI, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (“Pasithea” or the “Company”) (Nasdaq: KTTA; KTTAW), a clinical-stage biotechnology company developing PAS-004, a next-generation m...
Pasithea Therapeutics prices 80M shares at 75c in public offering
Pasithea Therapeutics (KTTA) announced the pricing of a public offering of 80,000,000 shares of the Company’s common stock at an offering price of $0.75 per share of common stock. The
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock
Extends cash runway through at least the first half of 2028 Led by Vivo Capital, Janus Henderson Investors, Coastlands Capital, Columbia Threadneedle Investments, Adage Capital Partners, and Squadron ...
Pasithea Therapeutics announces $1M award by ALS Association
Pasithea Therapeutics (KTTA) announced that the ALS Association has awarded a Hoffman ALS Clinical Trial Award grant worth ~$1 million to study PAS-004 in ALS patients. The award was given
Pasithea Therapeutics completes cohort 7 in Phase 1 trial of PAS-004
Pasithea Therapeutics (KTTA) announced safety, PK and PD data from Cohort 7 in its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a doc...
Pasithea Therapeutics Announces Completion of Cohort 7 in Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients, with Positive Safety, Pharmacokinetic (PK), and Pharmacodynamic (PD) Data
-- Zero Treatment Related Adverse Events observed during Cohort 7 (37mg capsules) DLT period – --Cohort 7 Pharmacokinetic (PK) profile continues to demonstrate dose-proportionality and Cmax/Cmin ratio
Pasithea says tablet PK exposure increases proprtionally with dose increase
Pasithea Therapeutics (KTTA) announced tablet PK data from ongoing Phase 1/1b open-label study evaluating PAS-004 in adult patients with neurofibromatosis type 1 with symptomatic and inoperable, incom...
Pasithea Therapeutics Announces Positive PAS-004 Tablet Pharmacokinetic (PK) Data in Ongoing Phase 1/1b Trial in Adult NF1 Patients
-- Tablet PK exposure increases proportionally with an increase in dose -- -- More favorable PK properties in tablets enable a lower dose to achieve the same exposure as the capsule formulation, with...
Why Is Pasithea Therapeutics Stock (KTTA) Down Today?
Pasithea Therapeutics stock fell after the company posted poor interim clinical trial data.
Pasithea Therapeutics announces interim data from PAS-004 trial
Pasithea Therapeutics (KTTA) announced interim Phase 1 data from its ongoing first-in-human trial evaluating PAS-004 in patients with MAPK pathway-driven advanced solid tumors with a documented RAS, N...
Pasithea Therapeutics Announces Positive Phase 1 Data Including Partial Response, Demonstrating Monotherapy Clinical Activity and Favorable Safety Profile for PAS-004 in Advanced Cancer Study
In new data, MEK inhibitor PAS-004 shows monotherapy partial response, favorable PK and safety profile, supporting best-in-class potential for NF1-PN.
Pasithea announces activation of trial site at UAB for study of PAS-004
Pasithea Therapeutics (KTTA) announced activation of a new U.S. clinical trial site at the University of Alabama at Birmingham, UAB, for its ongoing Phase 1/1b open-label study evaluating PAS-004 in
Pasithea Therapeutics Announces Activation of Clinical Trial Site at University of Alabama at Birmingham for Ongoing Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
MIAMI, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyc...
Pasithea Therapeutics announces activation of two South Korean trial sites
Pasithea Therapeutics (KTTA) announced activation of two South Korean clinical trial sites participating in its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics, PK, an...
Pasithea Therapeutics Announces Activation of Clinical Trial Sites in South Korea for Phase 1/1b Trial of PAS-004 in Adult NF1 Patients
Pasithea Tx (Nasdaq: KTTA) activates South Korea trial sites, dosing first NF1 patient in Phase 1/1b NF1 study at Asan Medical Ctr. and Severance Hospital.
Pasithea announces enrollment of cohort 2 in Phase 1/1b trial of PAS-004
Pasithea Therapeutics (KTTA) announced that the external Safety Review Committee recommended that the Company’s Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pha...